N
Nodexus
Nodexus is democratizing access to live single cells for applications including gene editing, drug development, and more
About Nodexus
Nodexus operates in the biotechnology sector, focusing on the development and commercialization of an integrated platform designed for single-cell enrichment and analysis. The company's core product, the NX One platform, is a low-cost, compact system that simplifies the workflow for delivering enriched single cells from a variety of samples, including stem cells, transfected cell lines, cultured cell lines, dissociated tissue, and whole blood. This platform is particularly valuable for researchers who require accurate dispensing of individual live targets for further analyses.
Nodexus primarily serves academic and commercial research institutions, biotechnology companies, and pharmaceutical firms. The company operates in the life sciences market, which is characterized by a high demand for advanced cell analysis technologies. Nodexus's business model revolves around the sale of its NX One platform and associated consumables, generating revenue through both initial equipment sales and recurring purchases of consumable supplies.
The NX One platform offers highly sensitive cell screening, characterization, and active isolation capabilities, making it a versatile tool for various research applications. By providing a cost-effective and efficient solution for single-cell analysis, Nodexus aims to address the growing need for precise and reliable cell manipulation technologies in the research community.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- San Jose, United States
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 58.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2021 | $30M | $120M | RA Capital Management · Section 32 | ↗ |
| GRANTOther financing | Jul 2019 | — | — | US National Science Foundation | — |
Growth signals
Latest recorded traffic for Nodexus is 2.8K monthly website visits, up 16.7% over the last three months. Nodexus's team declined 33.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Palapa Ventures
US National Science Foundation
Series A2 investors entered at this stage
Other known investors8 additional known investors
Berkeley SkyDeck Accelerator
University of California, Berkeley
Astia
California Life Sciences
Joyo Wijaya
QB3
Sean Fee
Small Business Innovation Research
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nodexus on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nodexus’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.